The sale is part of a pre-arranged 10b5-1 plan and is modest relative to market cap. Monitor upcoming quarterly filings for any change in insider selling patterns or option exercise volume.
GILD drugs
GILD drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 5 $167.57entry
- T+1 · 11d ago −0.41%α −0.72% · $166.89
- T+5 · 5d ago +0.23%α −3.06% · $167.95
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
CEO Daniel O'Day filed a Form 144 notice to sell 112,429 shares of Gilead Sciences common stock, valued at approximately $18.8 million, to be acquired through stock option exercises over the next three months. The filing also discloses prior 10b5-1 plan sales totaling about $9.8 million in the preceding weeks. While the sale is large in absolute terms, it represents a small fraction of the company's $211B market cap and appears to be part of a pre-arranged trading plan.
Key Facts
- CEO Daniel O'Day filed Form 144 to sell 112,429 shares of common stock
- Estimated aggregate value of proposed sale: $18,828,484.63
- Shares to be acquired via exercise of stock options over the next three months
- Prior 10b5-1 plan sales disclosed: 15,000 shares on 11/02/2026 ($2.55M), 15,881 shares on 10/30/2026 ($2.78M), 15,000 shares on 10/01/2026 ($2.22M), 15,000 shares on 09/01/2026 ($2.23M)
- Total prior 10b5-1 sales: ~$9.78M
- Market cap: $211.3B; proposed sale represents ~0.009% of market cap
- Filing date: 2026-11-04; proposed sale date: same day
Financial Impact
CEO proposes to sell ~$18.8M in stock, with ~$9.8M already sold under 10b5-1 plan in prior months; total insider selling ~$28.6M over ~2 months
Risk Factors
- CEO selling a large absolute dollar amount could signal personal diversification or reduced conviction, though 10b5-1 plans mitigate timing concerns
- Continued insider selling may weigh on sentiment if it accelerates
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-010699 |
| Document: 0001950047-26-010699-index.html | 0001950047-26-010699 |
| Document: 0001950047-26-010699.txt | 0001950047-26-010699 |
Track record
30 reports on GILD
5 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +22.38% at T+60 after the Aug 13, 2026 report. 5 of 8 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $167.58 Now $167.58 +0.00% settles Feb 16
- Nov 16, 2026today Insider Cluster Neutral 2/10 Entry $167.71 Now $167.58 −0.08% settles Feb 12
- Nov 13, 20264d ago Court Ruling Bullish 4/10 Entry $170.99 Now $167.58 −1.99% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $168.08 Now $167.58 −0.30% settles Feb 11
- Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $170.87 Now $167.58 −1.93% settles Feb 8
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $169.32 Now $167.58 −1.03% settles Feb 5
- Nov 4, 202612d ago 144 Neutral 3/10 Viewing Entry $167.57 Now $167.58 +0.01% settles Feb 3
- Oct 30, 202617d ago 144 Neutral 3/10 Entry $170.33 Now $167.58 −1.61% settles Jan 29
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $170.68 Now $167.58 −1.82% settles Jan 28
- Oct 22, 202625d ago Institutional Cluster Bearish 4/10 Entry $156.04 Now $167.58 −7.40% settles Jan 21
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers